In Vivo Expansion of Activated Foxp3+ Regulatory T Cells and Establishment of a Type 2 Immune Response upon IL-33 Treatment Protect against Experimental Arthritis

• Published in: The Journal of immunology (1950) 2016-09, Vol.197 (5), p.1708-1719
• Main Authors: Biton, Jérôme, Khaleghparast Athari, Sara, Thiolat, Allan, Santinon, François, Lemeiter, Delphine, Hervé, Roxane, Delavallée, Laure, Levescot, Anais, Roga, Stéphane, Decker, Patrice, Girard, Jean-Philippe, Herbelin, André, Boissier, Marie-Christophe, Bessis, Natacha
• Format: Article
• Language: English
• Subjects: Animals; Antigens, CD - genetics; Apyrase - genetics; Arthritis, Experimental; Arthritis, Rheumatoid - chemically induced; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - immunology; Autoimmune Diseases - immunology; Collagen - administration & dosage; Cytokines - blood; Disease Models, Animal; Eosinophils; Human health and pathology; Interleukin-33 - immunology; Interleukin-33 - pharmacology; Interleukin-33 - therapeutic use; Life Sciences; Mice; Mice, Inbred DBA; Spleen - cytology; Spleen - drug effects; T-Lymphocytes, Regulatory - immunology; Th2 Cells - immunology
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.1502124

IL-33 is strongly involved in several inflammatory and autoimmune disorders with both pro- and anti-inflammatory properties. However, its contribution to chronic autoimmune inflammation, such as rheumatoid arthritis, is ill defined and probably requires tight regulation. In this study, we aimed at deciphering the complex role of IL-33 in a model of rheumatoid arthritis, namely, collagen-induced arthritis (CIA). We report that repeated injections of IL-33 during induction (early) and during development (late) of CIA strongly suppressed clinical and histological signs of arthritis. In contrast, a late IL-33 injection had no effect. The cellular mechanism involved in protection was related to an enhanced type 2 immune response, including the expansion of eosinophils, Th2 cells, and type 2 innate lymphoid cells, associated with an increase in type 2 cytokine levels in the serum of IL-33-treated mice. Moreover, our work strongly highlights the interplay between IL-33 and regulatory T cells (Tregs), demonstrated by the dramatic in vivo increase in Treg frequencies after IL-33 treatment of CIA. More importantly, Tregs from IL-33-treated mice displayed enhanced capacities to suppress IFN-γ production by effector T cells, suggesting that IL-33 not only favors Treg proliferation but also enhances their immunosuppressive properties. In concordance with these observations, we found that IL-33 induced the emergence of a CD39(high) Treg population in a ST2L-dependent manner. Our findings reveal a powerful anti-inflammatory mechanism by which IL-33 administration inhibits arthritis development.